Press Release Archive

November 19, 2009 - FDA Approves Intravenous Formulation Of Pfizer’s Revatio® (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension

(BUSINESS WIRE)--Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations. Revatio is indicated for the treatment of adult patients with pulmonary arterial hypertension (WHO Group I) to improve exercise

November 19, 2009 - FDA Advisory Committee Finds Data Support the Claim That SPIRIVA® HandiHaler® Reduces COPD Exacerbations

(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee voted 11 to 1 that clinical data included in a supplemental new drug application (sNDA) provide substantial and convincing evidence to support the claim that SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) reduces exacerbations (worsening of symptoms) in patients with chronic obstructive pulmonary

November 18, 2009 - Pfizer Encourages Families To Bring Their Dogs To This Year’s Holiday Celebration

(BUSINESS WIRE)--Pfizer Animal Health wants families to talk with one another about bringing the family dog along when they travel to their Thanksgiving-to-New Year’s celebrations. For most people, the holidays are a time of joy and celebration. But some people feel guilty or sad about leaving their dog behind because they consider their dog part of the family. “In addition, this year, many families are

November 18, 2009 - FDA Advisory Committee Finds Data Support the Safety and Effectiveness of Prevnar 13™ Vaccine for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in

November 17, 2009 - Pfizer and DNDi Advancing International Research Efforts In The Fight Against Neglected Tropical Diseases

(BUSINESS WIRE)--NEW YORK

November 17, 2009 - Pfizer Submits New Pediatric Data For Lipitor® (Atorvastatin) To The European Medicines Agency (EMEA)

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission. Approximately one in 500 people suffer from an inherited disorder, called Familial Hypercholesterolemia (FH), which causes high levels of LDL-

November 9, 2009 - Pfizer Announces Global Research Network

(BUSINESS WIRE)--Pfizer Inc today announced its global research and development network, marking an important step in implementing a new R&D model as part of the integration of Pfizer and Wyeth. This global network brings together scientific strengths from both companies, continues efforts to increase research productivity, focuses disease-area research in single locations and more efficiently uses the company’s real estate

November 4, 2009 - Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX® (Varenicline) Compared With Placebo

(BUSINESS WIRE)--New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p<0.0001). These findings were presented by investigators at CHEST 2009, the 75th annual international

November 2, 2009 - Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer’s Disease

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer’s disease (AD). The CONTACT study will assess as primary endpoints the potential benefits of adding dimebon to ongoing treatment with donepezil HCI tablets, them

October 29, 2009 - Pfizer Completes Consent Solicitation

(BUSINESS WIRE) Pfizer today announced that it has received the requisite consents to amend certain provisions of the indenture governing the following outstanding debt securities (the Securities) of Wyeth, its wholly owned subsidiary: Debt Security Description

October 29, 2009 - Pfizer’s Board Of Directors Approves Shareholder Advisory Vote On Executive Compensation

(BUSINESS WIRE) Pfizer Inc. (NYSE: PFE) announced that its Board of Directors has approved giving shareholders an advisory vote on executive compensation. The vote will first occur at Pfizer’s Annual Meeting of Shareholders in 2010 and will take place on a biennial basis thereafter. “The Board’s action continues Pfizer’s long tradition of seeking and responding to shareholder input on compensation and other

October 22, 2009 - Pfizer Declares a 16-Cent Fourth-Quarter 2009 Dividend

(BUSINESS WIRE) The board of directors of Pfizer Inc (NYSE: PFE) today declared a 16-cent fourth-quarter 2009 dividend on the company’s common stock, payable December 1, 2009, to shareholders of record at the close of business on November 6, 2009. The fourth-quarter 2009 cash dividend will be the 284th consecutive quarterly dividend paid by Pfizer.

October 19, 2009 - Pfizer Reports Third-Quarter 2009 Results

(BUSINESS WIRE) Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Third-Quarter Year-to-Date

October 19, 2009 - New Pfizer Animal Health is Unveiled with Acquisition of Wyeth

(BUSINESS WIRE) A new Pfizer Animal Health was unveiled last week as Pfizer's acquisition of Wyeth, including its subsidiary Fort Dodge Animal Health, was completed. Pfizer Animal Health is now the world’s leader in the discovery, development, manufacture and sales of veterinary vaccines and medicines for livestock and companion animals. The acquisition of many of Fort Dodge’s U.S. products allows Pfizer Animal Health to

October 17, 2009 - CP-690,550, Pfizer’s Oral JAK Inhibitor, Demonstrates Response Both Alone And In Combination With Methotrexate At 24 Weeks In Patients With Active Rheumatoid Arthritis

(BUSINESS WIRE) Pfizer Inc announced today that 24-week data from two clinical studies of the oral JAK inhibitor, CP-690,550, confirmed statistically significant ACR20 response and DAS28 remission rates for several doses versus placebo when given alone or in combination with methotrexate for patients with active rheumatoid arthritis (RA). The findings, which were presented this week at the 2009 ACR/ARHP Annual Scientific Meeting in

October 15, 2009 - Pfizer Commences Consent Solicitation for Amendments to Wyeth Indenture

(BUSINESS WIRE) Pfizer today announced that it has commenced a consent solicitation to amend certain provisions of the indenture governing the following outstanding debt securities (the Securities) of Wyeth, its wholly owned subsidiary: Aggregate Debt Security

October 15, 2009 - Pfizer And Wyeth Become One: Working Together For A Healthier World™

(BUSINESS WIRE) Pfizer Inc (NYSE: PFE) today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets. It has medicines in numerous growing therapeutic areas, a robust pipeline,

October 15, 2009 - Pfizer Completes Acquisition Of Wyeth

(BUSINESS WIRE) fizer (NYSE: PFE) and Wyeth (NYSE: WYE) announced today that Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merger agreement and approval by Wyeth shareholders. Under the terms of the transaction, each outstanding share of Wyeth common stock has been converted into the right to receive $33 in cash (without interest) and 0.985 of a

October 14, 2009 - Pfizer Receives Clearance From The U.S. Federal Trade Commission And The Canadian Competition Bureau For Wyeth Acquisition

(BUSINESS WIRE) Pfizer Inc (NYSE:PFE) today announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Wyeth. In addition, Pfizer has received approval from the Canadian Competition Bureau for the pending acquisition. With the receipt of these clearances, Pfizer has now satisfied the

October 13, 2009 - Pfizer Announces Settlement And License Agreement With Mylan Related To Vfend®

(BUSINESS WIRE) Pfizer Inc today announced that it has entered into an agreement with two subsidiaries of Mylan Inc. relating to a generic version of Vfend® (voriconazole), an antifungal agent. The agreement is limited to the tablet form of Vfend and does not cover Pfizer’s Vfend products for intravenous use or oral suspension. Pursuant to the agreement, Mylan will have the right to market voriconazole tablets in the

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.